PIKTOR controlled disease in 83% of patients, so why did Faeth Therapeutics stock crash 42%?
Faeth’s PIKTOR produced a 33% response rate in advanced endometrial cancer, but shares fell 42% as investors weighed efficacy and toxicity.
Pharma & Biotech